Apellis Pharmaceuticals Inc. (APLS)
$41.03
$0.00 (0.00%)As on 15-May-2026 16:00EDT
Market cap
$5,251 Mln
Revenue (TTM)
$1,029 Mln
P/E Ratio
38.3
P/B Ratio
12.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.5 %
-
ROCE
-- %
-
Industry P/E
28.71
-
EV/EBITDA
29.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
128,021,277
10 Years Aggregate
CFO
$-2,275.87 Mln
EBITDA
$-2,333.04 Mln
Net Profit
$-2,844.78 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Apellis Pharmaceuticals (APLS)
| 63.3 | 0.4 | 89.1 | 145.7 | -22.4 | -1.5 | -- |
|
BSE Sensex
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Apellis Pharmaceuticals (APLS)
| -21.3 | -46.4 | 15.8 | 9.4 | -17.3 | 86.8 | 132.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Apellis Pharmaceuticals (APLS)
|
41.0 | 5,251.4 | 1,029.0 | 133.3 | 14.5 | 32.7 | 38.3 | 12.7 |
| 11.9 | 3,805.9 | 3,045.9 | 122.4 | 13.8 | -- | 32.2 | 105.4 | |
| 227.7 | 11,139.5 | 708.2 | -188.3 | -25.6 | -293.5 | -- | 204.8 | |
| 66.1 | 12,668.3 | 566.0 | -725.9 | -89.0 | -- | -- | 123.7 | |
| 56.4 | 5,496.4 | 769.1 | 47.9 | 5.4 | 7.5 | 146.3 | 8.8 | |
| 13.6 | 11,417.2 | 353,471.6 | 45,087.2 | 16.1 | 12.8 | 25.8 | 2.8 | |
| 19.9 | 10,808.1 | 4,893.0 | -242.0 | -1.5 | -3.7 | -- | 1.8 | |
| 7.7 | 5,308.5 | 7,682.7 | 438.7 | 15.9 | 7.5 | 11.1 | 0.9 | |
| 213.2 | 4,418.7 | 274.5 | 153.6 | 76.6 | 15.8 | 28.7 | 4.4 | |
| 13.4 | 3,508.4 | 6,163.0 | 246.0 | 15.7 | 27.2 | 14.4 | 3.9 |
Shareholding Pattern
View DetailsAbout Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of... paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts. Address: 100 Fifth Avenue, Waltham, MA, United States, 02451 Read more
-
Co-Founder, President, CEO & Director
Dr. Cedric Francois M.D., Ph.D.
-
Co-Founder, President, CEO & Director
Dr. Cedric Francois M.D., Ph.D.
-
Headquarters
Waltham, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Apellis Pharmaceuticals (APLS)
What is the current share price of Apellis Pharmaceuticals Inc (APLS) Today?
The share price of Apellis Pharmaceuticals Inc (APLS) is $41.03 (NASDAQ) as of 15-May-2026 16:00 EDT. Apellis Pharmaceuticals Inc (APLS) has given a return of -22.45% in the last 3 years.
What is the current PB & PE ratio of Apellis Pharmaceuticals Inc (APLS)?
The P/E ratio of Apellis Pharmaceuticals Inc (APLS) is 38.34 times as on 12-May-2026, a 34 premium to its peers’ median range of 28.71 times.
The P/B ratio of Apellis Pharmaceuticals Inc (APLS) is 12.66 times as on 12-May-2026, a 111 premium to its peers’ median range of 6.00 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
145.86
|
8.82
|
|
2024
|
-20.00
|
17.31
|
|
2023
|
-13.48
|
36.62
|
|
2022
|
-8.40
|
32.27
|
|
2021
|
-5.32
|
19.99
|
What is the 52 Week High and Low of Apellis Pharmaceuticals Inc (APLS)?
The 52-week high and low of Apellis Pharmaceuticals Inc (APLS) are Rs 41.13 and Rs 16.10 as of 17-May-2026.
What is the market cap of Apellis Pharmaceuticals Inc (APLS)?
Apellis Pharmaceuticals Inc (APLS) has a market capitalisation of $ 5,251 Mln as on 12-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Apellis Pharmaceuticals Inc (APLS)?
Before investing in Apellis Pharmaceuticals Inc (APLS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.